Sabbagh, Marwan N., Agro, Albert, Bell, Joanne, Aisen, Paul S, Schweizer, Edward, Galasko, Douglas

Objective: To evaluate the safety and tolerability of PF-04494700, an oral inhibitor of receptor for advanced glycation end products, in patients with mild-to-moderate dementia of the Alzheimer type.; Methods: Patients aged 50 years and older who met the National Institute of Neurological and Communicative Diseases and Stroke/Alzheimer’s Disease and Related Disorders Association criteria for Alzheimer […]

Petiau, Christophe, Onen, Hakki, Delgado, Antonio, Touchon, Jacques

Presents a study which aims to explore sleep related outcomes in patients with mild moderate Alzheimer’s disease (AD) initiating acetylcholinesterase inhibitor therapy. This study is a prospective, observational, longitudinal, multicentre survey evaluating sleep quality in AD patients initiating acetylcholinesterase inhibitor (AChEI) treatment. Data for this study were collected at AChEI initiation and after 3 to […]

Ihara, Masafumi, Nishino, Madoka, Taguchi, Akihiko, Yamamoto, Yumi, Hattori, Yorito, Saito, Satoshi, Takahashi, Yukako, Tsuji, Masahiro, Kasahara, Yukiko, Takata, Yu, Okada, Masahiro

Goal: Combinatorial therapy directed at both vascular and neurodegenerative aspects of dementia may offer a promising strategy for treatment of dementia, which often has a multifactorial basis in the elderly. We investigated whether the phosphodiesterase III inhibitor cilostazol, which is often used in the prevention of stroke and peripheral artery disease, may delay cognitive decline […]

Galasko, D., Bell, J., Mancuso, J. Y., Kupiec, J. W., Sabbagh, M. N., van Dyck, C., Thomas, R. G., Aisen, P. S.

Objective: To examine safety, tolerability, and efficacy of PF-04494700, an inhibitor of the receptor for advanced glycation end products (RAGE), in mild to moderate Alzheimer disease (AD).; Methods: Double-blind, placebo-controlled trial at 40 academic centers (United States). Subjects with AD and Mini-Mental State Examination score 14-26 were randomized to PF-04494700 60 mg/day × 6 days, […]

Darreh-Shori, Taher, Hosseini, Sharokh Makvand, Nordberg, Agneta

Despite three decades of intensive research in the field of Alzheimer’s disease (AD) and numerous clinical trials of new therapeutic agents, cholinesterase inhibitors (ChEIs) are still the mainstay of therapeutics for AD and dementia with Lewy bodies. Pharmacodynamic analyses of ChEIs provide paradoxical observations. Treatment with the rapidly reversible, noncarbamylating ChEIs (donepezil, galantamine, and tacrine) […]